(605033)"Shaanxi Meibang Pharmaceutical Group Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 605033 · · 12 pages · Chinese
Summary by 6ix AI
It includes key financial data, non-recurring profit and loss items, and changes in financial indicators. The report also provides information on the total number of shareholders and the status of major shareholders' holdings. The financial statements included are unaudited and cover the consolidated balance sheet and cash flow statement.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shaanxi Meibang Pharmaceutical Group Co., Ltd. on 6ix
Earlier from Shaanxi Meibang Pharmaceutical
- Announcement on Providing Guarantees for Wholly-owned Subsidiaries
- Announcement on Capital Increase in a Wholly-owned Subsidiary and Establishment of a Hong Kong Wholly-owned Subsidiary
- Announcement on the Results of Shareholding Reduction by Shareholders
- Announcement on the Results of Shareholding Reduction by Certain Shareholders
- Announcement on Change of Shareholder Name
Later from Shaanxi Meibang Pharmaceutical
- (605033)"Shaanxi Meibang Pharmaceutical Group Co., Ltd."Announcement on Providing Guarantees for Wholly-owned Subsidiaries
- (605033)"Shaanxi Meibang Pharmaceutical Group Co., Ltd."Announcement on Implementation of Dividend Distribution for the First Three Quarters of 2026
Follow Shaanxi Meibang Pharmaceutical into a list and get an email when it puts out news.
Follow Shaanxi Meibang Pharmaceutical